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Changes in Lipid Levels and Incidence of Cardiovascular 
Events Following Tofacitinib Treatment in Patients With 
Psoriatic Arthritis: A Pooled Analysis Across Phase III and 
Long- Term Extension Studies
Dafna D. Gladman,1 Christina Charles-Schoeman,2 Iain B. McInnes,3 Douglas J. Veale,4 Bruce Thiers,5 
Mike Nurmohamed,6 Dani Graham,7 Cunshan Wang,7 Thomas Jones,8 Robert Wolk,7 and Ryan DeMasi8
Objective. The risk of cardiovascular disease (CVD) is higher in patients with psoriatic arthritis (PsA) compared 
to the general population. Tofacitinib is an oral Janus kinase inhibitor for the treatment of PsA. Because tofacitinib 
increases circulating lipid levels in some patients, we evaluated CVD risk factors and major adverse cardiovascular 
events (MACE) in patients with active PsA receiving tofacitinib 5 or 10 mg twice daily plus conventional synthetic 
disease- modifying antirheumatic drugs.
Methods. Data were pooled from 2 phase III studies (Efficacy and Safety of Tofacitinib in Psoriatic Arthritis [OPAL 
Broaden] and Tofacitinib in Patients with Psoriatic Arthritis With Inadequate Response to TNF Inhibitors [OPAL Be-
yond]) and 1 ongoing long- term extension (Open- Label Extension Study of Tofacitinib in Psoriatic Arthritis [OPAL 
Balance], data cutoff January 2017; database not locked). Outcomes included fasting lipid levels, blood pressure, 
hypertension- related adverse events (AEs; including hypertension, high blood pressure, and increased blood pres-
sure), and MACE.
Results. Overall, 783 tofacitinib- treated patients were included. Percentage increases from baseline in low- 
density lipoprotein cholesterol (LDL-c) and high-density lipoprotein cholesterol (HDL-c) levels ranged from 9% to 14% 
for tofa citinib 5 mg and 10 mg at 3 and 6 months; no meaningful changes in LDL-c:HDL-c or total cholesterol:HDL-c 
ratios were observed. Blood pressure remained stable for 24 months. Fifty- eight patients (7.4%) had hypertension- 
related AEs; none were fatal (incidence rate [IR] per 100 patient- years 4.81 [95% confidence interval (95% CI) 3.65–
6.22]). Five patients (0.6%) had MACE (IR 0.24 [95% CI 0.05–0.70]); 2 were fatal.
Conclusion. Serum lipid level increases at month 3 following tofacitinib treatment in PsA were consistent with 
observations in rheumatoid arthritis and psoriasis. The IR of hypertension- related AEs and MACE was low; long- term 
follow- up is ongoing.
Clinicaltrials.gov identifiers: NCT01877668, NCT01882439, and NCT019 
76364.
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INTRODUCTION
Psoriatic arthritis (PsA) is an immune- mediated systemic 
inflammatory disease with multiple disease manifestations, 
including peripheral arthritis, enthesitis, dactylitis, and spondylitis, 
together with skin and nail psoriasis (1). The risk of cardiovascular 
disease (CVD) and cardiometabolic disorders is higher in patients 
with PsA compared with the general population (2,3) and is con-
sidered comparable with rates in patients with rheumatoid arthritis 
(RA) and diabetes mellitus (4–7). Therefore, management of CVD 
risk factors is recommended (2,8,9). In addition, an association 
has been suggested between peripheral joint inflammation and 
lipid dysregulation in PsA (10).
Treatment options for PsA aim to achieve optimal control 
of disease activity through the suppression of inflammation (11). 
Tofacitinib is an oral Janus kinase inhibitor for the treatment of 
PsA. The efficacy and safety of tofacitinib have been demon-
strated in 2 phase III studies (Efficacy and Safety of Tofacitinib in 
Psoriatic Arthritis [OPAL Broaden] [12] and Tofacitinib in Patients 
with Psoriatic Arthritis With Inadequate Response to TNF Inhib-
itors [OPAL Beyond] [13]) and 1 ongoing long- term extension 
(LTE) study (Open- Label Extension Study of Tofacitinib in Psoriatic 
Arthritis [OPAL Balance] [14]).
The objective of this post hoc analysis was to better under-
stand the changes in cholesterol levels and other selected CVD 
risk factors as well as to evaluate the incidence of major adverse 
cardiovascular events (MACE), a composite of CVD deaths, non-
fatal myocardial infarction, and nonfatal stroke in patients with 
active PsA receiving tofacitinib 5 and 10 mg twice daily (BID) in 
combination with conventional synthetic disease- modifying anti-
rheumatic drugs (csDMARDs) using data from 2 phase III studies 
(OPAL Broaden [12] and OPAL Beyond [13]) and 1 ongoing LTE 
study (OPAL Balance [14]).
PATIENTS AND METHODS
Data were analyzed for patients who received ≥1 dose of 
tofacitinib 5 or 10 mg BID or placebo, pooled across 2 phase 
III studies and 1 LTE study of the 2 phase III studies in patients 
with active PsA. OPAL Broaden (12) was a phase III, 12- 
month, double- blind, placebo- and active- controlled parallel- 
group study in adult patients with active PsA who were naive 
to tumor necrosis factor inhibitors (TNFi), who were receiving 
1 background csDMARD, and who had a prior inadequate 
response to ≥1 csDMARD. Patients were randomized 2:2:2:1:1 
to tofacitinib 5  mg  BID, tofacitinib 10  mg  BID, adalimumab 
40 mg subcutaneously every 2 weeks, placebo advancing to 
tofacitinib 5 mg BID after 3 months, or placebo advancing to 
tofacitinib 10 mg BID after 3 months. OPAL Beyond (13) was a 
phase III, 6- month, double- blind, placebo- controlled, parallel- 
group study in adults with active PsA who were receiving 1 
background csDMARD and who had an inadequate response 
to ≥1 prior TNFi. Patients were randomized 2:2:1:1 to receive 
tofacitinib 5 mg BID, tofacitinib 10 mg BID, placebo advancing 
to tofacitinib 5  mg  BID after 3 months, or placebo advanc-
ing to tofacitinib 10  mg  BID after 3  months. OPAL Balance 
(14) is an ongoing, open- label LTE study that enrolled patients 
who had participated in OPAL Broaden or OPAL Beyond. Data 
up to January 2017 (database not locked; data may change) 
were included in the current analysis, which included up to 3 
years of tofacitinib exposure per patient. All patients received 
open- label tofacitinib 5  mg BID upon entry into OPAL Bal-
ance. The tofacitinib dosage could be increased to 10 mg BID 
at the investigator’s discretion after 1 month, and could be 
decreased from 10 mg BID to 5 mg BID for safety reasons at 
any time. (For information on data sharing, see Supplementary 
Appendix 1, available on the Arthritis Care & Research web 
site at http://onlin elibr ary.wiley.com/doi/10.1002/acr.23930/ 
abstract.)
Patient eligibility and disposition. Eligible patients were 
age ≥18 years, had been diagnosed with PsA for ≥6 months prior 
to study participation, fulfilled the Classification criteria for Pso-
riatic Arthritis (15), and had active plaque psoriasis at screening 
and active arthritis (≥3 swollen and ≥3 tender/painful joints) at both 
screening and baseline (defined at the initiation of OPAL Broaden 
and OPAL Beyond) (12,13).
Assessments. Baseline demographics and patient 
characteristics from the corresponding qualifying study were 
used as baseline in the LTE. Pooled phase III data comprised 
phase III studies only and included placebo data up to month 
3; pooled phase III and LTE data comprised tofacitinib data 
from the phase III and LTE studies (patients who were origi-
nally randomized to placebo were included, but only from the 
day that treatment with tofacitinib was initiated). Continuous 
SIGNIFICANCE & INNOVATIONS
• The magnitude and dose dependency of increases 
in lipid levels to month 6 in patients with psoriatic 
arthritis (PsA) receiving tofacitinib were consistent 
with findings in patients with rheumatoid arthritis 
(RA) and psoriasis.
• As increases in low-density lipoprotein cholesterol 
were paralleled by increases in high-density lipo-
protein cholesterol (HDL-c), no meaningful changes 
in the total cholesterol:HDL-c ratio were observed.
• The incidence of major adverse cardiovascular 
events in patients with active PsA was within the 
range reported in prior tofacitinib studies in RA and 
psoriasis, and was generally consistent with data 
reported in the literature for other PsA treatments.
• There is no evidence at this time that treatment 
of PsA with tofacitinib is associated with increased 
cardiovascular risk.
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laboratory measurements such as fasting lipid levels and 
C- reactive protein (CRP) level analyses included pooled 
data from months 0 to 6 of phase III studies only (including 
tofacitinib 5 mg BID, tofacitinib 10 mg BID, and placebo up 
to month 3 only). Blood pressure measurements and data 
on hypertension were pooled across the phase III and LTE 
 studies using tofacitinib- exposed patients only and were iden-
tified using a Standardized Medical Dictionary for Regulatory 
Activities (MedDRA, version 19.1) query for hypertension (nar-
row). All hypertension- related events were reported as adverse 
events (AEs) and included the terms hypertension, high blood 
pressure, and increased blood pressure.
Table 1. Baseline demographics and characteristics from the phase III studies OPAL Broaden and OPAL Beyond*
Characteristics
Tofacitinib 5 mg BID 
(n = 238)
Tofacitinib 10 mg BID 
(n = 236)
Placebo 
(n = 236)
Baseline demographics
Female, no. (%) 121 (50.8) 136 (57.6) 136 (57.6)
Age, years 49.5 ± 12.4 49.4 ± 11.7 48.4 ± 12.5
White, no. (%) 226 (95.0) 221 (93.6) 222 (94.1)
Body mass index, kg/m2 29.8 ± 6.3 30.2 ± 6.3 29.2 ± 5.6
Smoking history, no. (%)
Never smoked 139 (58.4) 140 (59.3) 158 (66.9)
Smoker 37 (15.5) 45 (19.1) 39 (16.5)
Ex- smoker 62 (26.1) 51 (21.6) 39 (16.5)
Baseline medical history, no. (%)
Diabetes mellitus† 29 (12.2) 37 (15.7) 34 (14.4)
Hypertension‡ 99 (41.6) 81 (34.3) 87 (36.9)
Dyslipidemia§ 60 (25.2) 67 (28.4) 55 (23.3)
Metabolic syndrome¶ 99 (41.6) 101 (42.8) 94 (39.8)
Lipid laboratory values
HDL-c, mg/dl 55.7 ± 16.9 56.5 ± 19.6 55.7 ± 17.5
LDL-c, mg/dl 116.8 ± 32.4 119.1 ± 37.2 114.6 ± 33.1
Triglycerides, mg/dl 146.7 ± 93.9 144.2 ± 150.4 137.3 ± 74.6
Baseline disease characteristics
Psoriatic arthritis duration, years 8.6 ± 7.9 7.5 ± 6.6 8.1 ± 7.5
Baseline PASDAS# 6.1 ± 1.2 6.2 ± 1.2 6.0 ± 1.2
Baseline HAQ DI 1.2 ± 0.7** 1.2 ± 0.6 1.2 ± 0.7
Baseline CPDAI with baseline BSA ≥3%†† 10.0 ± 2.5 10.4 ± 2.7 9.8 ± 2.8
Baseline swollen joint count 12.5 ± 10.3 12.3 ± 9.8 10.9 ± 8.9
C- reactive protein, mg/liter 12.3 ± 20.5 12.0 ± 21.9 11.3 ± 20.2
Baseline total psoriatic BSA, mean % ± SD‡‡ 10.0 ± 14.1 10.0 ± 12.6 12.0 ± 16.5
Relevant prior and concomitant medication, no. (%)
Prior TNFi 131 (55.0) 132 (55.9) 132 (55.9)
Prior non- TNFi bDMARDs§§ 11 (8.4) 14 (10.6) 11 (8.4)
TNFi naive 107 (45.0) 104 (44.1) 104 (44.1)
Concomitant methotrexate 186 (78.2) 180 (76.3) 193 (81.8)
Concomitant corticosteroid (day 1)¶¶ 67 (28.2) 37 (15.7) 49 (20.8)
Concomitant NSAIDS (day 1) 144 (60.5) 125 (53.0) 132 (55.9)
* Values are the mean ± SD unless indicated otherwise. BID = twice daily; HDL-c = high-density lipoprotein cholesterol; LDL-c 
= low-density lipoprotein cholesterol; PASDAS = Psoriatic Arthritis Disease Activity Score; HAQ DI = Health Assessment Ques-
tionnaire disability index; CPDAI = Composite Psoriatic Disease Activity Index; BSA = body surface area; TNFi = tumor necro-
sis factor inhibitor; bDMARD = biologic disease- modifying antirheumatic drug; NSAID = nonsteroidal antiinflammatory drug. 
† Included patients who met ≥1 of the following criteria: diagnosis of diabetes mellitus recorded at screening; receiving any 
concomitant antidiabetic medication; glycosylated hemoglobin (HbA1C) ≥6.5% at baseline, or baseline fasting plasma glucose 
≥126 mg/dl, if HbA1C data were not available. 
‡ Patients who were reported as having hypertension on the Cardiovascular Risk Factor case report form at baseline. 
§ Defined as HDL-c <40 mg/dl (male) and <50 mg/dl (female) from baseline/screening data. 
¶ Defined as patients with ≥3 components of the metabolic syndrome: obesity (waist circumference for male and female, 
respectively: US, Canada, Europe, Russia: ≥102 cm and ≥88 cm; Asian, including Japanese: ≥90 cm and ≥80 cm; ethnic central 
and South American: ≥90 cm and ≥80 cm); dyslipidemia: triglycerides ≥150 mg/dl, including patients receiving medications 
for lowering triglycerides, and HDL-c <40 mg/dl (male) and <50 mg/dl (female); elevated blood pressure: systolic ≥130 mm 
Hg or diastolic ≥85 mm Hg, including patients receiving antihypertensive medication; and fasting glucose ≥100 mg/dl, includ-
ing patients receiving antidiabetic medication. 
# For this subset of patients, n = 229, 230, and 231, respectively. 
** n = 237. 
†† For this subset of patients, n = 160, 147, and 166, respectively. 
‡‡ For patients with BSA >0% at baseline. 
§§ Patients who were treated with any non- TNFi bDMARD or both TNFi bDMARDs and non- TNFi bDMARDs were included in 
the prior non- TNFi bDMARDs category. For this subset of patients, n = 131, 132, and 132, respectively. 
¶¶ Oral systemic corticosteroid use at baseline (maximum allowed dose of 10 mg/day of prednisone equivalent). 
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MACE were pooled across the phase III and LTE studies 
and were evaluated and classified by an external, independent 
adjudication committee, who were blinded to treatment; events 
were confirmed using prespecified criteria (see Supplementary 
Appendix 2, available on the Arthritis Care & Research web 
site at http://onlin elibr ary.wiley.com/doi/10.1002/acr.23930/ 
abstract).
Disease activity was measured using the Psoriatic Arthri-
tis Disease Activity Score (PASDAS) (16), the Composite Psori-
atic Disease Activity Index (CPDAI) (17), and the Disease Activity 
Index for Psoriatic Arthritis (18). In the pooled CVD event analy-
ses across phase III and LTE studies, patients who received ≥1 
dose of tofacitinib were considered as a single group (all tofacitinib 
doses). The average tofacitinib 5 mg BID treatment group con-
sisted of patients with an average total daily dose of <15 mg from 
day 1 with tofacitinib; the average tofacitinib 10 mg BID treatment 
group consisted of patients with an average total daily dose of ≥15 
mg from day 1 with tofacitinib.
Ethics approval. The institutional review boards and/or 
independent ethics committees approved the studies at each 
investigational center. Studies were conducted in compliance 
with the Declaration of Helsinki and International Conference on 
Harmonisation Good Clinical Practice Guidelines. All patients pro-
vided written, informed consent.
Statistical analysis. Continuous data were summarized 
descriptively. In addition, changes from baseline in the CRP 
level were analyzed using a mixed model for repeated measures 
(MMRM), with the fixed effects of treatment, visit, treatment- by- 
visit interaction, geographic location, study, and baseline value; 
an unstructured covariance matrix was used and P values were 
unadjusted. Two separate MMRM analyses were performed, 
using data from week 2 to month 3, and for month 4 to month 6 
using data from week 2 to month 6.
Discrete data were summarized using proportions and/or 
incidence rates (IRs) adjusted for person- time using the study 
drug. IR estimates (patients with events per 100 patient- years 
[PYs]) were calculated and included events occurring up to 
28 days beyond the last dose (or to the data cutoff date for 
the ongoing LTE study). Exposure was defined as the total 
follow- up time calculated up to the day of the first event within 
the event counting period for patients who experienced the 
event or the last dose day plus an additional risk period of 28 
days beyond the last dose (or to the data cutoff date for the 
ongoing LTE study, whichever was earlier) for patients with-
out events. These definitions were chosen because the active 
reporting period for AEs was up to and including 28 calendar 
days after the last administration of the investigational product, 
and because reporting to the company safety database may 
occur at any time regardless of the time elapsed from the last 
administration of the study drug or since study completion. 
Inclusion of all events (numerator) without regard to elapsed 
time may inflate IR estimations, because the exposure time 
(denominator) is not similarly increased. Exact Poisson 95% 
confidence intervals (95% CIs, adjusted for PYs) are provided 
for the IR data (19,20).
RESULTS
Patients. Overall, 783 tofacitinib- treated patients were 
included in the analysis, pooled across the phase III and LTE 
studies. The total exposure to tofacitinib (all tofacitinib doses) 
was 1,237.9 PYs, with a median duration of exposure of 594.0 
days (range 1–1,196 days). Baseline demographics and char-
acteristics, including CVD risk factors, were generally similar 
between treatment groups in the phase III studies. Baseline 
demographics and characteristics from the pooled phase III 
studies are shown in Table 1. The mean age ranged from 48.4 to 
49.5 years across treatment groups and the majority of patients 
were white (range 93.6–95.0%) and female (range 50.8–57.6%). 
At baseline, the duration of diagnosed PsA ranged from 7.5 to 
8.6 years, and patients had high disease activity (PASDAS range 
6.0–6.2; CPDAI range 9.8–10.4).
Figure 1. Mean percentage change from baseline in lipids at A, month 3 and B, month 6 (pooled phase III data), based on patients with a 
baseline and ≥1 postbaseline measurement. Patients randomized to placebo were advanced to tofacitinib 5 or 10 mg twice daily (BID) at month 
3. LDL- c = low- density lipoprotein cholesterol; HDL- c = high- density lipoprotein cholesterol; N = number of patients with value at the given time 
point.
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Outcomes. Mean percentage increases from baseline 
in low-density lipoprotein cholesterol (LDL-c) and high-den-
sity lipoprotein cholesterol (HDL-c) ranged from ~9% to 14% 
for tofacitinib 5 and 10 mg BID at 3 months (LDL-c 9.2% and 
14.0%; HDL-c 10.0% and 14.0%, respectively) and stabilized 
through month 6 (LDL-c 9.9% and 14.3%; HDL-c 9.0% and 
13.9%, respectively; pooled phase III data) (Figure 1). Percent-
age changes from baseline to month 3 or month 6 in LDL-c 
and HDL-c appeared to be greater with the 10 mg BID dose 
than the 5 mg BID dose. Similar mean percentage changes 
from baseline were also seen for total cholesterol and triglyc-
erides at both time points (3 months: total cholesterol 8.5% 
and 12.1%; triglycerides 9.3% and 16.8%; 6 months: total 
cholesterol 8.2% and 13.7%; triglycerides 6.6% and 20.4%, 
respectively). No meaningful changes were observed in lipid 
ratios (3 months: LDL-c:HDL-c 2.2 and 2.3; total cholesterol:H-
DL-c 3.9 and 3.9; 6 months: LDL-c:HDL-c 2.3 and 2.3; total 
cholesterol:HDL-c 3.9 and 3.9 for tofacitinib 5 mg and 10 mg 
BID, respectively) (Figure 2).
Treatment with tofacitinib 5 mg and 10 mg BID provided 
a significant least squares mean reduction in CRP levels from 
baseline versus placebo as early as week 2 (tofacitinib 5 mg 
–6.3 mg/liter; tofacitinib 10  mg –7.0 mg/liter; both P < 0.001 
versus placebo [0.2 mg/liter]; pooled phase III data). Significant 
reductions from baseline in CRP level were also reported for 
both doses of tofacitinib versus placebo at month 3 (tofacitinib 5 
mg –5.1 mg/liter; tofacitinib 10 mg –5.8 mg/liter; both P < 0.001 
versus placebo [0.4 mg/liter]), and reductions were maintained 
to month 6 (tofacitinib 5 mg –6.4 mg/liter; tofacitinib 10 mg –8.3 
mg/liter; no placebo comparison at month 6) (Figure 3). There 
was no dose response to tofacitinib treatment in terms of mean 
systolic and diastolic blood pressure over 24 months (pooled 
phase III and LTE data); neither dose of tofacitinib was associ-
ated with meaningful changes from baseline (Figure 4).
Figure 2. Mean lipid ratios at baseline, month 3, and month 6 for A, low- density lipoprotein cholesterol (LDL- c):high- density lipoprotein 
cholesterol (HDL- c) and B, total cholesterol:HDL- c (pooled phase III data), based on patients with a baseline and ≥1 postbaseline measurement. 
Patients randomized to placebo were advanced to tofacitinib 5 or 10 mg twice daily (BID) at month 3. N = number of patients with value at the 
given time point.
Figure 3. Least squares (LS) mean change from baseline in C- reactive protein (CRP) level over time (pooled phase III data). Two separate 
analyses were performed. A mixed model for repeated measures (MMRM) was used to generate results with data from week 2 to month 3, 
as well as results from week 2 to month 6. Each analysis was based on an MMRM with the fixed effects of treatment, visit, treatment- by- visit 
interaction, geographic location, study, and baseline value; an unstructured covariance matrix was used. BID = twice daily; N = number of 
patients with value at the given time point; *** = P < 0.001 versus placebo.
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Across the phase III and LTE studies, 58 patients with 
hypertension- related AEs (including the terms hypertension, high 
blood pressure, and increased blood pressure) were reported 
and none were fatal (Table 2). Of these, 2 hypertension events 
led to patient discontinuation (both receiving tofacitinib 5 mg). A 
further 2 events were classified as serious AEs (one each receiv-
ing tofacitinib 5 mg and 10 mg at the time of the event). When 
comparing doses, the IRs of hypertension events were similar 
between those patients receiving an average dose of tofacitinib 
5 mg BID and those receiving 10 mg BID.
Figure 4. A, Mean systolic, and B, mean diastolic sitting blood pressure (BP) over 24 months (pooled phase III and long- term extension data). 
Includes all tofacitinib- exposed patients who had both a baseline and ≥1 postbaseline observation; baseline values are from the OPAL Broaden 
and OPAL Beyond studies. Average tofacitinib 5 mg twice daily (BID) comprised patients with an average total daily dose of <15 mg from day 
1 using tofacitinib. Average tofacitinib 10 mg BID comprised patients with an average total daily dose of ≥15 mg from day 1 using tofacitinib. N 
= number of patients with value at the given time point.
Table 2. Patients with hypertension- related AEs and treatment- emergent adjudicated MACE (pooled phase III and LTE data)*
Pooled phase III data (0–3 months) Pooled phase III and LTE data
Tofacitinib  
5 mg BID 
(n = 238)
Tofacitinib  
10 mg BID 
(n = 236)
Placebo 
(n = 236)
Average  
tofacitinib  
5 mg BID 
(n = 482)
Average  
tofacitinib  
10 mg BID 
(n = 301)
All tofacitinib 
(n = 783)
Total hypertension- 
related AEs, no. (%)
5 (2.1) 6 (2.5) 5 (2.1) 36 (7.5) 22 (7.3) 58 (7.4)
Exposure, PYs† 54.0 53.3 52.8 758.3 447.9 1,206.1
Total hypertension- 
related AEs‡
9.26 (3.01–21.61) 11.26 (4.13–24.50) 9.48 (3.08–22.12) 4.75 (3.33–6.57) 4.91 (3.08–7.44) 4.81 (3.65–6.22)
Total MACE, no. (%) 0 0 0 2 (0.4) 1 (0.3) 3 (0.4)
Ischemic stroke 0 0 0 0 1 (0.3) 1 (0.1)
Myocardial  
infarction
0 0 0 1 (0.2) 0 1 (0.1)
Sudden cardiac 
death§
0 0 0 1 (0.2) 0 1 (0.1)
Exposure, PYs† 54.6 54.4 53.7 788.6 469.8 1,258.44
Total MACE¶ 0 (0–6.75) 0 (0–6.78) 0 (0–6.87) 0.25 (0.03–0.92) 0.21 (0.01–1.19) 0.24 (0.05–0.70)
* Values are the incidence rate (95% confidence interval) unless indicated otherwise. Hypertension- related adverse events (AEs; including  the 
terms hypertension, high blood pressure, and increased blood pressure) were defined using a Standardized Medical Dictionary for Regulatory 
Activities query (version 19.1). All causalities included all defined events regardless of treatment relatedness. MACE = major adverse cardiovascu-
lar event; LTE = long- term extension; BID = twice daily; PYs = patient- years. 
† PY exposure was the time to the day of the first hypertension- related AE, subject to an observation period of 28 days beyond the last dose or 
to the data cutoff date. 
‡ Defined as the number of patients with events per 100 PYs. 
§ Two additional events in the pooled phase III and LTE population, both in patients receiving tofacitinib 5 mg, were reported beyond the 
 observation period and were not included in the incidence rate calculation. 
¶ Defined as the number of patients with events per 100 PYs. Two additional events in the pooled phase III and LTE population, both in patients 
receiving tofacitinib 5 mg, were reported beyond the observation period and were not included in the incidence rate calculation. 
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In total, 5 patients (0.6%) experienced a MACE across 
the phase III and LTE studies (Table  2), of which 2 were fatal 
(both adjudicated to be unrelated to treatment) and 3 were non-
fatal. In 2 patients, MACE (1 fatal and 1 nonfatal) were outside 
the 28- day observation period and were therefore not included 
in the IR calculation. The overall IR for MACE events, excluding 
the 2 patients where the event took place beyond the 28- day 
observation period, was 0.24 (95% CI 0.05–0.70) patients with 
events per 100 PYs. No patients had congestive heart failure. 
Further details of the fatal and nonfatal MACE can be found in 
Supplementary Appendix 2, available on the Arthritis Care & 
Research web site at http://onlin elibr ary.wiley.com/doi/10.1002/
acr.23930/ abstract.
DISCUSSION
In the OPAL Broaden and OPAL Beyond phase III stud-
ies in patients with active PsA, dose- dependent increases 
in lipid levels of 10–15% were observed following treatment 
with tofacitinib 5 and 10 mg BID at month 3, with no appre-
ciable further changes at month 6. HDL-c increased concur-
rently with other lipids, and no meaningful changes in LDL-c: 
HDL-c or total cholesterol:HDL-c ratios were observed. These 
changes are consistent with observations of lipid levels in other 
tofacitinib studies in patients with RA and psoriasis (21–24). 
Furthermore, both tofacitinib 5 and 10 mg BID provided sig-
nificant and consistent reductions in CRP level from baseline 
compared with placebo over 3 months, and the proportion 
of patients reporting hypertension, as defined by the Med-
DRA Hypertension Standardized MedDRA Query, was similar 
between treatment groups, with comparable IRs. Although the 
risk of CVD and cardiometabolic disorders is higher in patients 
with PsA compared with the general population (2,3,25), and 
as lipid ratios, CRP levels, and blood pressure/hypertension 
are known CVD risk factors (26–28), taken together, this analy-
sis showed no further increase in CVD risk following treatment 
with tofacitinib 5 or 10 mg BID. This conclusion is consistent 
with the observed IR of MACE, which was found to be gener-
ally consistent with that seen in a population- based longitudi-
nal study of PsA (IR 0.57) (29), and in those patients receiving 
either secukinumab (IR 0.6) (30) or ustekinumab (IR 1.23) (31) 
for the treatment of PsA or psoriasis. In addition, IRs were 
similar to those observed in patients who received tofacitinib 
treatment in pooled analyses of patients with RA (IR range 
0.19–0.58) (21,24) and psoriasis (IR 0.37) (22).
Suppression of circulating cholesterol levels in the setting of 
active systemic inflammation, such as in RA, has long been rec-
ognized (26,32–34). However, compared with controls, elevated 
LDL-c and triglycerides have been observed (35) in PsA, with 
rates of hypertriglyceridemia and metabolic syndrome higher in 
patients with PsA than in patients with RA (36). Dyslipidemia in 
PsA is possibly a consequence of skin and joint inflammation in 
PsA associated with elevations of inflammatory cytokines such as 
TNF and interleukin- 6 (37), which can induce hepatic synthesis 
of CRP (2). Other factors, such as obesity and diet, may also be 
involved. The insidious onset of PsA may also mean that patients 
with PsA are exposed to active disease for longer than patients 
with other inflammatory diseases, putting them at greater risk for 
lipid changes (36). In addition, the burden of systemic inflamma-
tion, along with oxidative stress and disease activity, have been 
demonstrated to play a role in increasing the risk of CVD and 
therefore MACE in patients with PsA (3,38). To further understand 
the link between lipids and CVD risk in patients with PsA, inves-
tigating nontraditional lipid risk factors such as HDL- associated 
paraoxonase 1 activity and HDL- associated serum amyloid A may 
be beneficial. Indeed, paraoxonase 1 activity has been found to 
be decreased in patients with PsA compared with healthy controls 
(38), and in patients with psoriasis, treatment with tofacitinib has 
been found to both increase paraoxonase 1 activity and decrease 
HDL- associated serum amyloid A (23).
Of note, both the US product information and European 
Union (EU) summary of product characteristics (SmPC) state that 
maximum increases in lipid parameters, including total choles-
terol, LDL-c, and HDL-c, were generally observed within 6 weeks 
of treatment initiation. Furthermore, both the product information 
and SmPC recommend that lipid parameters should be assessed 
8 weeks after starting treatment (and approximately 4–8 weeks 
thereafter in the US, or 8 weeks in the EU), and that patients should 
be managed according to clinical guidelines (39,40). Increases in 
total cholesterol and LDL-c associated with tofacitinib may be 
reduced to  pretreatment levels with statin therapy (41).
Limitations of this analysis include the fact that comparisons 
with placebo were limited to the 3- month placebo- controlled por-
tion of the phase III studies, and thus the overall extent and length 
of exposure to placebo was less than to tofacitinib.  However, 
since the differences in lipid changes between 3 months and 
6 months were minimal, the 3- month placebo- controlled period 
appears to be a sufficient duration for lipid evaluation. In addi-
tion, the evaluation of MACE and hypertension events over time 
was limited by the sample size and extent of exposure, and 
consequently, due to the long latency period of MACE, a study 
of this length may not provide sufficient data. However, when 
compared with the larger RA and psoriasis data sets of pooled 
data from randomized trials and LTE studies (6,300 patients 
with 21,886 PYs of exposure for RA [data cutoff April 4, 2016; 
database not locked, data may change]); 3,662 patients with 
8,537 PYs of exposure for psoriasis [data cutoff May 10, 2016; 
database not locked, data may change]), the IRs were compa-
rable. Furthermore, in a prospective, observational 5- year study, 
embedded within the US Corrona RA registry of patients with 
RA, rates of CVD, which included MACE as part of the defini-
tion, were  comparable between patients initiating tofacitinib and 
patients initiating biologic DMARDs (42). Finally, caution should 
be applied when comparing studies due to different population 
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characteristics, capture and definition of events, and few events 
of interest in the PsA tofacitinib development program.
In patients with PsA, the magnitude and dose depend-
ency of increases in lipid levels to month 6 were consistent with 
findings in tofacitinib studies in patients with RA and psoriasis. 
Because increases in LDL-c were paralleled by increases in 
HDL-c, no meaningful changes in total cholesterol:HDL-c ratio 
were observed. In addition, rates of hypertension were not 
affected by treatment dose, CRP levels decreased, and the inci-
dence of MACE was low and similar to other PsA therapies. Of 
note, the incidence of MACE in patients with active PsA was 
within the range reported in prior tofacitinib studies in RA and 
psoriasis (21–24) and was generally consistent with data reported 
in the literature for other PsA treatments (29–31). In conclusion, 
there is no evidence at this time that treatment of PsA with tofac-
itinib is associated with increased CVD risk; however, longer- term 
follow- up is needed and is ongoing. Low numbers of patients with 
hypertension- related AEs and MACE were noted.
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